Serum albumin-protamine conjugate for biocompatible platform for targeted delivery of therapeutic macromolecules

Journal of Biomedical Materials Research - Part A

Volumn 102, Issue 8, 2014, Pages 2481-2490

  Absar, Shahriar ^a   Nahar, Kamrun ^a   Choi, Suna ^a   Ahsan, Fakhrul ^a   Yang, Victor C ^b   Kwon, Young M ^a,c  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c NOVA SOUTHEASTERN UNIVERSITY   (United States)

Author keywords

albumin as a carrier; albumin based delivery; localized thrombolysis; prodrug strategy for macromolecules

Indexed keywords

AMINO ACIDS; BIOCOMPATIBILITY;

ALBUMIN AS A CARRIER; ALBUMIN-BASED DELIVERY; BINDING CHARACTERISTICS; ION-EXCHANGE CHROMATOGRAPHY; PRODRUGS; THERAPEUTIC POTENTIALS; THROMBOLYSIS; TISSUE PLASMINOGEN ACTIVATOR;

MACROMOLECULES;

HUMAN SERUM ALBUMIN; PROTAMINE; TISSUE PLASMINOGEN ACTIVATOR; BIOMATERIAL; HEPARIN; MACROMOLECULE; PEPTIDE; SERUM ALBUMIN; THIOL DERIVATIVE;

ARTICLE; BIOCOMPATIBILITY; CHEMICAL REACTION; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; CYTOTOXICITY; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG STABILITY; ENZYME ACTIVITY; FLUORESCENCE; HEMOLYSIS; HUMAN; ION EXCHANGE CHROMATOGRAPHY; MACROMOLECULE; MOLECULAR WEIGHT; SURFACE PROPERTY; THIOLATION; THROMBOCYTE ACTIVATION; ADMINISTRATION AND DOSAGE; CHEMISTRY; ELECTROSPRAY MASS SPECTROMETRY; METABOLISM; PHARMACOLOGY; PROTEIN STABILITY; THERAPEUTIC USE;

BIOCOMPATIBLE MATERIALS; CHROMATOGRAPHY, ION EXCHANGE; DRUG DELIVERY SYSTEMS; HEPARIN; HUMANS; MACROMOLECULAR SUBSTANCES; PEPTIDES; PLATELET ACTIVATION; PROTAMINES; PROTEIN STABILITY; SERUM ALBUMIN; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; SULFHYDRYL COMPOUNDS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 84903268481     PISSN: 15493296     EISSN: 15524965     Source Type: Journal    
DOI: 10.1002/jbm.a.34916     Document Type: Article

References (22)

1. Fanali G, di Masi A, Trezza V, Marino M, Fasano M, Ascenzi P,. Human serum albumin: From bench to bedside. Mol Aspects Med 2012; 33: 209-290.
2. Morales J,. Defining the role of insulin detemir in Basal insulin therapy. Drugs 2007; 67: 2557-2584.
3. Schnitzer JE,. gp60 is an albumin-binding glycoprotein expressed by continuous endothelium involved in albumin transcytosis. Am J Physiol 1992; 262: H246-H254.
4. Tiruppathi C, Song W, Bergenfeldt M, Sass P, Malik AB,. Gp60 activation mediates albumin transcytosis in endothelial cells by tyrosine kinase-dependent pathway. J Biol Chem 1997; 272: 25968-25975.
5. Wang Z, Tiruppathi C, Minshall RD, Malik AB,. Size and dynamics of caveolae studied using nanoparticles in living endothelial cells. ACS Nano 2009; 3: 4110-4116.
6. Guo Q, Wang H, Zhao Y, Wang H, Zeng F, Hua H, Xuc Q, Huang Y,. Cell-penetrating albumin conjugates for enhanced doxorubicin delivery. Polym Chem 2013; DOI: 10.1039/C3PY00742A.
7. Elsadek B, Kratz F,. Impact of albumin on drug delivery-New applications on the horizon. J Control Release 2012; 157: 4-28.
8. Graeser R, Esser N, Unger H, Fichtner I, Zhu A, Unger C, Kratz F,. INNO-206, the (6-maleimidocaproyl hydrazone derivative of doxorubicin), shows superior antitumor efficacy compared to doxorubicin in different tumor xenograft models and in an orthotopic pancreas carcinoma model. Invest New Drugs 2010; 28: 14-19.
9. Kratz F, Warnecke A, Scheuermann K, Stockmar C, Schwab J, Lazar P, Drückes P, Esser N, Drevs J, Rognan D, Bissantz C, Hinderling C, Folkers G, Fichtner I, Unger C,. Probing the cysteine-34 position of endogenous serum albumin with thiol-binding doxorubicin derivatives. Improved efficacy of an acid-sensitive doxorubicin derivative with specific albumin-binding properties compared to that of the parent compound. J Med Chem 2002; 45: 5523-33.
10. Absar S, Choi S, Yang VC, Kwon YM,. Heparin-triggered release of camouflaged tissue plasminogen activator for targeted thrombolysis. J Control Release 2012; 157: 46-54.
11. Absar S, Choi S, Ahsan F, Cobos E, Yang VC, Kwon YM,. Preparation and characterization of anionic oligopeptide-modified tissue plasminogen activator for triggered delivery: An approach for localized thrombolysis. Thromb Res 2012; 131: e91-e99.
12. Leach JK, O'Rear EA, Patterson E, Miao Y, Johnson AE,. Accelerated thrombolysis in a rabbit model of carotid artery thrombosis with liposome-encapsulated and microencapsulated streptokinase. Thromb Haemost 2003; 90: 64-70.
13. Ware S, Donahue JP, Hawiger J, Anderson WF,. Structure of the fibrinogen gamma-chain integrin binding and factor XIIIa cross-linking sites obtained through carrier protein driven crystallization. Protein Sci 1999; 8: 2663-2671.
14. Patel B, Gupta V, Ahsan F,. PEG-PLGA based large porous particles for pulmonary delivery of a highly soluble drug, low molecular weight heparin. J Control Release 2012; 162: 310-320.
15. Liu J, Guo S, Li Z, Liu L, Gu J,. Synthesis and characterization of stearyl protamine and investigation of their complexes with DNA for gene delivery. Colloids Surf B Biointerfaces 2009; 73: 36-41.
16. Naik SS, Liang JF, Park YJ, Lee WK, Yang VC,. Application of "ATTEMPTS" for drug delivery. J Control Release 2005; 101: 35-45.
17. Absar S, Nahar K, Kwon YM, Ahsan F,. Thrombus-targeted nanocarrier attenuates bleeding complications associated with conventional thrombolytic therapy. Pharm Res 2013; 30: 1663-1676.
18. Gupta AS, Huang G, Lestini BJ, Sagnella S, Kottke-Marchant K, Marchant RE,. RGD-modified liposomes targeted to activated platelets as a potential vascular drug delivery system. Thromb Haemost 2005; 93: 106-114.
19. Chang LC, Lee HF, Chung MJ, Yang VC,. PEG-modified protamine with improved pharmacological/pharmaceutical properties as a potential protamine substitute: Synthesis and in vitro evaluation. Bioconjug Chem 2005; 16: 147-155.
20. Meng F, Manjula BN, Smith PK, Acharya SA,. PEGylation of human serum albumin: Reaction of PEG-phenyl-isothiocyanate with protein. Bioconjug Chem 2008; 19: 1352-1360.
21. Liang JF, Li Y, Yang VC,. The potential mechanism for the effect of heparin on tissue plasminogen activator-mediated plasminogen activation. Thromb Res 2000; 97: 349-358.
22. Berger H Jr, Pizzo SV,. Preparation of polyethylene glycol-tissue plasminogen activator adducts that retain functional activity: Characteristics and behavior in three animal species. Blood 1988; 71: 1641-1647.